Continuous glucose monitoring guides glucagon-like peptide 1-based therapy use and optimization in people with type 2 diabetes.

Abstract

Type 2 diabetes (T2D) is a large and growing epidemic. Importantly, new technologies and pharmaceutical options are improving the management of T2D. Continuous glucose monitoring (CGM) systems have advanced glucose-sensing technology, which has made it easier for users to monitor their glucose levels. Glucagon-like peptide 1-based therapies and dual agonists have similarly revolutionized the treatment of T2D. In this article, we present four cases of individuals with T2D who, in collaboration with their healthcare provider, used the data from their CGM systems to inform therapy changes, including the initiation and titration of glucagon-like peptide 1-based therapies. Combined use of CGM systems and glucagon-like peptide 1-based therapies could improve people's diabetes as well as their overall health.